Releases Details

Gaithersburg, MD, January 16, 2017 – MaxCyte®, Inc., developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today that Madhusudan V. Peshwa, PhD, Chief Scientific Officer, Executive Vice President, Cellular Therapies, will participate in the Phacilitate Cell & Gene Therapy World Conference taking place January 18-20, 2017, in Miami.

Dr. Peshwa will chair the session entitled “Refining Your Future Gene Editing Strategy: What Will be the Key Applications and Platforms” on January 19, beginning at 2:30 p.m. ET. He will also present during the session on pre-clinical results demonstrating a robust, scalable, and clinically-relevant level of targeted gene-correction of mutated CYBB gene in hematopoietic stem cells (HSC) obtained from X-linked chronic granulomatosis disease (CGD) patients (as ex vivo gene-corrected cell therapy for treatment of monogenic diseases).

“MaxCyte’s Proprietary GT® Flow Electroporation™ System is commercially and clinically validated in accelerating development of more than a dozen enhanced-potency cell therapy products,” said Doug Doerfler, Founder, President & CEO of MaxCyte, Inc. “We are excited by the results from our pre-clinical studies on gene-correction, and this exemplifies how MaxCyte continues to invest ahead of our platform-licensing partners to develop robust, scalable, clinically relevant cell therapy products and manufacturing processes. Our goal is to continue to provide value by de-risking and accelerating our partners’ future product development efforts in cutting-edge scientific and product development applications, including targeted immunotherapies and in gene-editing.”

More information can be found at //www.bioleaders-forum.com/__media/PDFs/Cell–26-Gene-Therapy-World-main-announcement.pdf.

# # #

About MaxCyte

MaxCyte is a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets. The Company’s patented Flow Electroporation™ Technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte’s high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company’s cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte’s customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information, visit /